Pharmaceutical company, Santen, has been developing a drug, intravitreal sirolimus, to treat noninfectious posterior segment uveitis. Uveitis is a type of eye inflammation, in which the uvea, which is the middle part of the eye that supplies blood to the retina, is damaged. To learn more about uveitis, click here.
Last week, the FDA shared some disappointing news for people who were anticipating a new treatment– the drug wasn’t approved.
To learn more about why this happened and what to expect next, read the source article at healio.com.
